Vitiligo induced by immune checkpoint inhibitors
in melanoma patients: an expert opinion
Emerging roles of coronavirus in autoimmune diseases
Use of Rescue Therapy with IVIG or Cyclophosphamide
in Juvenile Myositis
Systemic lupus erythematosus (SLE), the embodiment of a multi-organ autoimmune disease, results from hyperactivation of host-defence pathways and immune recognition of the most fundamental building blocks of life. In 2018, key advances have placed intestinal immunity and dysregulated expansions of candidate pathobionts at the forefront of SLE pathogenesis.
The Microbiome and Systemic Lupus Erythematosus
Systemic Lupus Erythematosus and dysbiosis in the
microbiome: cause or effect or both?
T-cell specific upregulation of Sema4A as risk factor for autoimmunity in systemic lupus erythematosus and rheumatoid arthritis
Connective tissue diseases (CTDs) are a group of chronic and disabling diseases that involve inappropriate or excessive immune responses. They include a wide variety of illnesses such as rheumatoid arthritis (RA), systemic sclerosis (SSc), systemic lupus
erythematosus (SLE) and Sjo¨gren’s syndrome (SS)
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that results in increased morbidity and mortality.
Under certain conditions, patients with SLE may be admitted to the
intensive care unit (ICU) secondary to infectious disease flare-ups
or other non-SLE disease conditions that are aggravated by SLE.
Autoimmune connective tissue diseases are clinically variable,
making biomarkers desirable for assessing future disease risk,
supporting early and accurate diagnosis, monitoring disease
activity and progression, selecting therapeutics and assessing